caa a22 4500 46912024X CHVBK 20180323133136.0 cr unu---uuuuu 170328e19920501xx s 000 0 eng 10.1007/BF02244958 doi (NATIONALLICENCE)springer-10.1007/BF02244958 Fluoxetine: a review of receptor and functional effects and their clinical implications [Elektronische Daten] [Charles Beasley, Daniel Masica, Janet Potvin] Downregulation of serotonin 5-HT1 receptors is the most frequently reported central nervous system neural effect of subchronic exposure to fluoxetine in rodents. However, downregulation of these receptors has not been universally demonstrated. Effects of subchronic exposure on 5-HT2 receptors are mixed. Fluoxetine exposure appears to have no effect on cholinergic muscarinic receptors. Effects on beta-adrenergic receptors are controversial, as only one laboratory has reported down-regulation. The majority of studies have failed to show an effect on beta-adrenergic-receptor-stimulated cAMP generation. Electrophysiologic studies support the concept that fluoxetine facilitates net serotonergic transmission through downregulation of presynaptic inhibitory autoreceptors. Data suggest that its subchronic specificity and selectivity distinguish fluoxetine from members of other classes of available antidepressants, making it a distinct therapeutic option. Springer-Verlag, 1992 Antidepressant nationallicence Behavior nationallicence cAMP nationallicence Electrophysiology nationallicence Fluoxetine nationallicence Receptors nationallicence Neuroendocrine nationallicence Serotonin nationallicence Beasley Charles Division of Clinical Neurosciences, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, 46285, Indianapolis, IN, USA aut Masica Daniel Division of Clinical Neurosciences, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, 46285, Indianapolis, IN, USA aut Potvin Janet Division of Clinical Neurosciences, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, 46285, Indianapolis, IN, USA aut Psychopharmacology Springer-Verlag 107/1(1992-05-01), 1-10 0033-3158 107:1<1 1992 107 213 https://doi.org/10.1007/BF02244958 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02244958 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Beasley Charles Division of Clinical Neurosciences, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, 46285, Indianapolis, IN, USA aut NATIONALLICENCE 700 1- Masica Daniel Division of Clinical Neurosciences, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, 46285, Indianapolis, IN, USA aut NATIONALLICENCE 700 1- Potvin Janet Division of Clinical Neurosciences, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, 46285, Indianapolis, IN, USA aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 107/1(1992-05-01), 1-10 0033-3158 107:1<1 1992 107 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer